Advances in the treatment of newly diagnosed glioblastoma

BMC Medicine

Minireview

Brett J. Theeler¹  Mark R. Gilbert² 

[1] Department of Neurology and John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Building 19, 20889, Bethesda, MD, USA;National Institutes of Health, 9030 Old Georgetown Road, 20892, Bethesda, MD, USA;

关键词: Glioblastoma;    High grade glioma;    Immunotherapy;    Checkpoint inhibitors;    Pseudoprogression;   

DOI  :  10.1186/s12916-015-0536-8

 received in 2015-07-23, accepted in 2015-11-13,  发布年份 2015

来源: Springer

【 摘 要 】

Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients.

【 授权许可】

CC BY   
© Theeler and Gilbert. 2015